Long-term safety of stimulant medications used to treat children with ADHD

Pediatric Annals

Volumn 37, Issue 1, 2008, Pages 37-45

  Lerner, Marc ^a,c   Wigal, Tim ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHYLPHENIDATE;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; APPETITE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BODY HEIGHT; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HEADACHE; HEART RATE AND RHYTHM; HUMAN; INSOMNIA; IRRITABILITY; LISTLESSNESS; LONG TERM CARE; NERVOUSNESS; OVERFOCUSING; PSYCHOSOCIAL WITHDRAWAL; REVIEW; SADNESS; SIDE EFFECT; SLEEP DISORDER; TIC; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; HUMANS; TIME; UNITED STATES;

EID: 39749107434     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/00904481-20080101-11     Document Type: Review

References (40)

1. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044.
2. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
3. Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs. 2003;5(12):787-794.
4. McMaster University Evidence-Based Practice Center. Treatment of Attention-Deficit Hyperactivity Disorder. Rockville, MD: Agency for Healthcare Research and Quality; 1999. Evidence Report/Technology Assessment no. 11, AHRQ Publication no. 99-E018 http://www.ahrq.gov/clinic/epcsums/adhdsum.htm. McMaster study ADHD 1999.
5. Swanson JM. Compliance with Stimulants for ADHD: issues and approaches for improvement. CNS Drugs. 2003;17(2):117-131.
6. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159(6):572-578.
7. Wolraich ML, McGuinn L, Doffing M. Treatment of attention-deficit/ hyperactivity disorder in children and adolescents: safety considerations. Drug Safety. 2007;30(1):17-26.
8. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43(5):559-567.
9. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1-10.
10. Nissen SE. ADHD Drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445-1448.
11. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21(1):92-95.
12. Findling RL, Biederman J, Wilens TE, et al, and the SLI381.301 and .302 Study Groups. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147(3):348-354.
13. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1015-1023.
14. Wilens TE, Biederman J, Lerner M; Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol. 2004;24(1):36-41.
15. Donner RM, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(5):706-712.
16. Klein R, Mannuzza S. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry. 1988. 45: 1131-1134.
17. Safer D, Allen R, Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med. 1972;287(5):217-220.
18. NIH Consensus Committee 1998. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). NIH Consensus Statement. 1998;16(2):1-37.
19. Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S. Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry. 2000;39(4):517-524.
20. Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Metrick J. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil. 2006;27(2):162-174.
21. Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(5):520-526.
22. Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006;45(4):415-421.
23. Faraone SV, Biederman J, Monuteaux M, Spencer T Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/ hyperactivity disorder on growth. J Child Adolesc Psychopharmacol. 2005;15(2):191-202.
24. Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B; Concerta Study Group. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45(5):527-537.
25. Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1138-1147.
26. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 Years in the MTA follow-up. J Am Acad Child Adolesc. Psychiatry. 2007;46(8):1015.
27. Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol. 2006;48(7):616-621.
28. Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol. 2004;14(2):185-194.
29. Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry. 2001;42(3):228-233.
30. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56(4):330-336.
31. Greenhill, LL, Kollins S, Abikoff H, et al. Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD. Am Acad Child Adolesc Psychiatry. 2006;45(11):1284-1293.
32. Wigal T, Greenhill L, Chuang S, McGough et al. Safety and Tolerability of Methylphenidate in Preschool Children With ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1294-1303.
33. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):180-187.
34. MTA Cooperative Group. A 14-Month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086.
35. Wigal T, Greenhill L, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children With ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1294-1303.
36. Swanson J, Greenhill L, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304-1313.
37. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 1989;49(2):5736-5747.
38. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Methylphenidate and Amphetamine, March 2005. Available at http://cerhr.niehs.nih.gov/chemicals/stimulants/amphetamines/Amphetamine_final. pdf and http://cerhr.niehs.nih.gov/chemicals/stimulants/methylphenidate/ MethylphenidateMonograph.pdf.
39. El-Zein RA, Abdel-Rahman SZ, Hay MJ, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 2005:230(2):1-8.
40. Preston RJ, Kollins SH, Swanson JM, et al. Comments on "Cytogenetic effects in children treated with methylphenidate" by El-Zein et al. Cancer Lett. 2005;230(2):292-294.